Pharma Insight Briefings

Speaker Name: Keyvan Djamarni 

  1. What are the current global trends driving the pharmaceutical sector you are working in? How does your company respond to those trends?

Drug delivery devices with additional digital/connectivity functions will become increasingly commonplace. These could offer significant benefits, for example, enabling electronic monitoring of patient compliance. We are exploring how “smart” technologies could be applied to our future inhalation and injectable devices. A continuing trend is the push towards self-administration of injectable therapeutics, driven by the desire to increase patient convenience and reduce burden for healthcare providers. Bespak partners with companies to develop devices to meet specific patient needs. Recent work resulted in the launch of a new pre-filled auto-injector for rheumatoid arthritis patients with reduced manual dexterity and grip strength.

2. What are the top challenges faced by the pharmaceutical sector you represent at this moment? How does your company deal with these challenges?

One challenge is delivering inhaled, complex drug combinations. In 2016, we signed an agreement to scale-up and supply proprietary pMDI valves and actuators for Astrazeneca’s Bevespi Aerosphere™ inhaler. This was the first approved product using AstraZeneca’s Co-Suspension™ Technology for the delivery of one or more indications from a single pMDI, and was recently launched in the US. Ocular therapeutic administration is also increasingly important, driving the need for solutions that allow precise delivery and distribution to eye tissue. We are working with a customer on a solution targeting the suprachoroidal space in the eye wall, with optimum drug distribution and release.

3. What topic are you presenting at the Pharma Insight Briefings and why is this subject so important to the market at this time?

There is growing demand to make administration of injectable therapeutics more comfortable and convenient for patients. To meet demand, innovative delivery devices are required, each designed for a specific patient group. Biopharmaceutical companies are increasingly outsourcing device development, taking advantage of the breadth of expertise and novel technologies offered by device CDMOs. It’s important for biopharmaceutical and device companies to work together to ensure the successful launch of a drug-device combination product. Using a case study, we will discuss the considerations that drug manufacturers need to make when bringing pen, auto, and on-body injectors to market.

4. What can attendees to your session expect to gain and which challenges does this content address? Why should they include your presentation in their agenda?

Highlighting how to create successful partnerships between biopharmaceutical and device companies, the session will cover the following topics: factors to consider when choosing a device company; use of consultants; human factors; training devices and connectivity. We will look at the challenges biopharmaceutical companies and their partners will face, as well as opportunities that partnerships offer to improve combination products that are increasing prevalent in Europe, NA and ROW.  As leading biopharmaceutical companies are becoming increasingly active in the device space, it important to learn from their experiences and understand market trends for self-injection devices, to inform your own strategic decisions.

5. How do you see your sector of the market evolving in the next 5 years?

Data and connectivity will become more important in device design. Device usage data collection will be routine for injectable and inhalation devices – the challenge will be sharing and interpreting this data for better treatment decisions and increased compliance.Respiratory device component demand will likely remain high, particularly due to the expected increase in approved generic/device inhaler combinations. The global injectable drug delivery market also has strong growth potential, expected to almost double to US$ 624 billion by 2021. More novel devices for other administration routes, such as nasal and ocular, will also be needed to support increased patient compliance.